A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03): Substudy 03A

Brief description of study

The purpose of the study is to evaluate the safety, efficacy and tolerability of one or more experimental arms for the treatment of advanced renal cell carcinoma (RCC). There are specific set of treatment arms and these arms are composed of investigational agents. The experimental arms include the following: MK-1308A+ Lenvatinib, MK-4280A + Lenvatinib, Pembrolizumab + Lenvatinib + MK-483, and Pembrolizumab + Lenvatinib + MK-6482. The reference arm includes Pembrolizumab + Lenvatinib. The combination of these investigational agents in the trial has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test these agents in the current trial.


Clinical Study Identifier: s20-00089
ClinicalTrials.gov Identifier: NCT04626479
Principal Investigator: Victor Ricardo Adorno Febles.
Other Investigator: David R. Wise.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.